process
small
sampl
volum
utilis
wide
varieti
applic
make
method
choic
today
molecular
laboratori
aid
fluoresc
signal
probe
measur
amplif
dna
pcr
cycl
point
exponenti
dna
accumul
realtim
pcr
abl
provid
broader
linear
dynam
rang
increas
assay
perform
determin
sensit
specif
precis
reproduc
due
consist
signal
intens
chang
exponenti
growth
phase
pcr
also
easili
adapt
quantit
report
howev
three
properti
uniqu
associ
quantit
realtim
pcr
quantif
standardis
lower
limit
result
accumul
fluoresc
signal
measur
pcr
cycl
reaction
cycl
signal
exce
predetermin
background
fluoresc
threshold
logarithm
phase
amplif
refer
cycl
threshold
c
c
valu
invers
proport
viral
copi
number
specimen
comparison
valu
extern
calibr
curv
intern
quantit
standard
initi
nucleic
acid
target
concentr
calcul
heid
steven
livak
william
livak
schmittgen
howev
accur
quantit
within
sampl
hinder
reli
sole
extern
standard
amplif
effici
individu
sampl
may
variabl
inconsist
utilis
standard
intern
refer
templat
rational
variabl
influenc
amplif
effici
exampl
amplif
detect
target
nucleic
acid
realtim
pcr
affect
templat
target
similarli
inhibit
amplif
effect
compens
allow
accur
quantit
figur
control
enhanc
incorpor
intern
refer
utilis
primer
sequenc
target
sinc
potenti
addit
effect
pcr
effici
two
target
elimin
thu
competit
realtim
pcr
strategi
reliabl
approach
nucleic
acid
quantit
diviacco
et
al
gilliland
perrin
bunn
stieger
demollier
ahlbornlaak
mou
wang
doyl
mark
zentilin
giacca
basi
major
presentday
virolog
assay
equal
import
utilis
appropri
quantit
standard
avail
ensur
accur
quantit
result
interlaboratori
correl
overal
standardis
standardis
report
viral
load
ensur
interlaboratori
consist
also
high
clinic
util
viral
load
monitor
set
foundat
establish
clinic
correl
critic
threshold
lead
better
manag
infect
treatment
critic
develop
clinic
guidelin
miller
et
al
wide
avail
assay
method
viral
target
specimen
type
lack
standard
refer
materi
hayden
et
al
viral
load
variabl
across
laboratori
rang
significantli
high
log
copiesml
specif
result
profici
testingextern
qualiti
assess
programm
well
interlaboratori
specimen
exchang
studi
demonstr
signific
variabl
quantit
result
assay
lack
appropri
standard
quantit
viral
target
use
competit
quantit
standard
qs
qs
compens
effect
inhibit
control
prepar
amplif
process
allow
accur
quantit
viral
target
specimen
competit
qs
contain
sequenc
ident
primer
bind
site
viral
target
ensur
equival
amplif
effici
uniqu
probe
bind
region
distinguish
two
amplicon
competit
qs
ad
specimen
known
copi
number
carri
subsequ
step
specimen
prepar
revers
transcript
applic
simultan
pcr
amplif
detect
viral
target
concentr
test
specimen
calcul
compar
viral
target
signal
solid
line
qs
signal
dash
line
specimen
control
b
presenc
inhibitor
qs
viral
target
equal
suppress
yield
accur
viral
load
calcul
c
introduct
hayden
et
al
pang
et
al
preiksaiti
et
al
wolff
heaney
neuwald
stelrecht
press
find
reinforc
fact
high
degre
variabl
discrep
clinician
unabl
compar
test
result
two
differ
laboratori
clinic
relev
cutoff
set
one
test
would
appli
result
anoth
without
standardis
qualiti
patient
care
dramat
impact
prevent
meaning
interlaboratori
comparison
patient
result
influenc
diseas
prevent
manag
programm
kraft
armstrong
caliendo
especi
critic
transplant
patient
may
initi
monitor
one
institut
transfer
anoth
longerterm
followup
receiv
result
longer
correl
therefor
whenev
possibl
viral
load
monitor
test
must
report
result
iuml
fulli
traceabl
higherord
first
intern
standard
must
gener
highli
accur
reliabl
result
base
robust
calibr
methodolog
excel
reproduc
across
dynam
rang
test
demonstr
colinear
standard
lastli
exist
two
distinct
endpoint
quantit
realtim
pcr
consider
result
interpret
report
lower
limit
detect
llodlod
lower
limit
quantit
lloqloq
two
limit
assess
differ
equival
either
definit
case
assign
valu
lod
also
refer
analyt
sensit
repres
lowest
viral
load
level
test
sampl
detect
clsi
theoret
viral
level
lod
detect
time
differenti
detect
undetect
result
lloq
hand
lowest
viral
level
within
linear
analyt
accept
rang
assay
clsi
word
lloq
lowest
point
accur
viral
load
assign
determin
detect
sampl
report
viral
load
common
misconcept
lod
assay
minimum
viral
level
detect
result
undetect
detect
viral
level
never
differenti
singl
theoret
viral
threshold
viral
level
less
lod
may
still
high
probabl
detect
probabl
span
broad
rang
lower
viral
titr
like
undetect
result
ultim
statist
probabl
favour
undetect
result
figur
lloq
equal
greater
lod
viral
load
assay
unusu
detect
loq
detectablebloq
result
report
cobb
et
al
detectablebloq
result
infer
actual
viral
concentr
sampl
lod
loq
clinic
demand
driven
shape
evolut
pcr
continu
gain
greater
understand
infect
monitor
treat
studi
natur
histori
diseas
progress
attribut
specif
viral
infect
need
sensit
accur
precis
reproduc
reliabl
quantit
measur
viral
level
becom
necess
deeper
understand
natur
histori
human
immunodefici
viru
hiv
infect
well
understood
progress
immunosuppress
onset
develop
clinic
diseas
strictli
associ
increas
viral
burden
furtado
kingsley
wolinski
ho
moudgil
alam
mathez
et
al
nicholson
et
al
schnittman
et
al
thu
quantit
realtim
pcr
critic
monitor
patient
infect
hiv
hufert
et
al
mellor
et
al
undergo
antiretrovir
therapi
art
ensur
viral
replic
suffici
effect
suppress
monitor
potenti
viral
resist
medic
dhh
hiv
monitor
maintain
viral
suppress
absolut
necessari
maintain
progressionfre
surviv
hivinfect
patient
also
reduc
subsequ
hiv
transmiss
cohen
et
al
diffenbach
due
signific
viral
load
monitor
maintain
viral
suppress
demand
likelihood
differ
test
result
given
differ
viral
concentr
viral
concentr
tend
proport
target
detect
increas
dot
line
increas
likelihood
detect
result
concentr
tend
lloq
dash
line
likelihood
detect
lloq
result
peak
concentr
tend
infin
proport
quantit
result
tend
solid
line
result
continu
increas
likelihood
detect
quantit
result
concentr
sum
three
type
report
result
alway
throughout
concentr
continuum
variat
result
report
exist
concentr
viral
level
approach
lloq
near
equal
likelihood
detect
quantit
detect
lloq
result
possibl
detect
result
decreas
concentr
shift
likelihood
increas
chanc
detect
lloq
detect
result
diagram
assum
lloq
llod
increasingli
sensit
assay
hiv
driven
innov
diagnost
test
continu
push
limit
lod
loq
ever
lower
glaubitz
et
al
sizmann
et
al
addit
amount
viral
dna
sampl
either
hepat
b
viru
hbv
cytomegaloviru
cmv
chronic
carrier
indic
activ
viral
replic
liver
cell
correl
liver
diseas
progress
chen
lin
et
al
chen
yang
et
al
emeri
et
al
humar
et
al
humar
kumar
boivin
caliendo
iloej
et
al
wursthorn
mann
wedemey
highlight
need
quantit
viral
level
chronic
diseas
monitor
similarli
hepat
c
viru
hcv
level
link
prognosi
treatment
outcom
trepo
treatment
respons
pearlman
ehleben
zeuzem
et
al
well
assess
sustain
virolog
respons
svr
cure
follow
treatment
pearlman
traub
recent
new
antivir
therapi
hcv
treatment
reli
target
specif
biolog
step
viral
replic
cycl
reliabl
quantit
monitor
viral
burden
specif
timepoint
ensur
treatment
complianc
resist
emerg
treatment
recommend
au
pockro
aasldidsaiasusa
alongsid
chang
clinic
need
sever
instrument
manufactur
innov
introduc
meet
newer
requir
first
pcrbase
diagnost
test
first
autom
system
introduc
earli
allow
improv
standardis
techniqu
increas
effici
reduct
error
contamin
meet
clinic
need
monitor
patient
infect
hiv
first
personalis
healthcar
diagnost
test
fda
approv
monitor
whether
art
work
whether
patient
optim
treatment
entir
system
introduc
earli
autom
upfront
sampl
prepar
step
lead
reduct
handson
time
increas
reliabl
reproduc
introduct
realtim
pcr
techniqu
enhanc
assay
perform
first
pcr
test
allow
simultan
amplif
detect
introduc
throughout
decad
improv
assay
instrument
began
push
boundari
detect
achiev
greater
greater
sensit
feat
proven
incred
relev
understand
risk
viral
load
rebound
virolog
failur
doyl
et
al
estevez
et
al
pascualpareja
et
al
recent
shortli
releas
two
new
higherord
standard
cmv
first
intern
standard
nist
cmv
standard
fulli
autom
realtim
quantit
pcr
assay
fda
approv
meet
laboratori
clinic
demand
standardis
instrument
reduc
assay
design
variabl
inconsist
across
laboratori
also
assay
standardis
report
intern
unit
provid
accuraci
across
entir
dynam
rang
achiev
calibr
traceabl
higherord
standard
fdaapprov
test
gain
widespread
use
interlaboratori
agreement
cmv
viral
load
result
truli
improv
kraft
et
al
object
test
innov
evolv
adapt
clinic
laboratori
need
patient
outcom
gap
identifi
gain
greater
understand
insight
clinic
progress
diseas
diseas
manag
technolog
achiev
facilit
advanc
qualiti
diagnost
patient
outcom
lifethreaten
ill
convert
chronicmanag
diseas
aid
viral
load
monitor
pressur
exist
develop
precis
accur
sensit
assay
turn
drive
develop
efficaci
drug
synergi
demonstr
valu
diagnost
integr
part
patient
care
continuum
applic
quantit
realtim
pcr
virolog
extens
especi
necessari
antibodi
seroconvers
delay
acut
infect
earli
diagnosi
essenti
dibiasi
tyler
thomson
et
al
immunocompromis
patient
may
optim
antibodi
respons
kadmon
et
al
diagnosi
congenit
perinat
acquir
viral
infect
park
streicher
rothberg
young
nelson
good
addit
critic
maintain
high
level
patient
care
stage
diseas
infect
figur
screen
test
design
one
key
paramet
mind
except
sensit
herman
gill
eng
fajardo
must
ensur
diseas
miss
popul
gener
free
risk
allow
appropri
earli
intervent
therebi
effect
reduc
mortal
morbid
although
tradit
applic
realtim
pcr
continuum
care
patient
manag
populationbas
screen
programm
recommend
often
utilis
nucleic
acid
test
nat
virolog
target
reli
immunoassay
antigen
test
nat
realtim
pcr
assay
still
integr
compon
donorelig
determin
ensur
donor
elig
donat
cell
tissu
use
human
cell
tissu
cellular
tissuebas
product
hctp
includ
haematopoiet
stemprogenitor
cell
organ
semen
type
donat
part
live
cadaver
hctp
donor
elig
grant
screen
show
donor
free
risk
factor
clinic
evid
infect
due
relev
communic
diseas
agent
diseas
hiv
type
hbv
hcv
west
nile
viru
wnv
fda
test
fda
test
recommend
stipul
hctp
test
hiv
hcv
may
includ
fdalicens
nat
blood
donor
screen
specif
fdalicens
nat
use
assess
infect
wnv
despit
fact
nat
test
provid
qualit
oppos
quantit
result
molecular
technolog
utilis
often
realtim
pcr
due
enhanc
accur
reliabl
result
fda
assay
addit
preemptiv
virolog
screen
posttranspl
may
reduc
subsequ
complic
provid
costeffect
manag
strategi
ever
preemptiv
therapi
utilis
routin
viral
screen
initi
therapi
first
indic
viraemia
prior
clinic
manifest
diseas
strategi
reduc
overal
morbid
mortal
posttranspl
compar
strategi
treatment
initi
onset
clinic
diseas
onberg
et
al
preemptiv
treatment
model
utilis
routin
screen
quantit
realtim
pcr
asymptomat
posttranspl
patient
shown
especi
effect
paediatr
patient
undergo
haematopoiet
stem
cell
transplant
uniqu
high
risk
cmv
epsteinbarr
viru
ebv
infect
ever
strategi
prospect
screen
utilis
quantit
realtim
pcr
assay
bk
polyoma
viru
bkv
recommend
part
routin
posttranspl
followup
kidney
transplant
sinc
earli
identif
manag
bkv
infect
may
prevent
futur
incid
polyoma
virusassoci
nephropathi
hirsch
et
al
kdigo
nat
realtim
pcr
also
utilis
vital
part
certain
screen
algorithm
center
diseas
control
cdc
current
recommend
hcv
rna
test
utilis
anyon
may
expos
hcv
within
preced
month
addit
nat
would
identifi
activ
hcv
infect
among
person
test
antihcv
posit
indetermin
antibodi
test
indic
need
referr
medic
evalu
care
cdc
hcv
viral
diagnost
test
use
determin
presenc
absenc
current
previou
infect
mani
viral
infect
present
similar
symptom
accur
diagnosi
critic
requir
uniqu
vastli
differ
intervent
andor
manag
strategi
histor
diagnosi
viral
infect
reli
viral
growth
cell
cultur
immunoassay
antigen
assay
elisa
haemagglutin
test
electron
microscopi
krishna
cunnion
introduct
molecular
method
includ
nat
realtim
pcr
assay
vastli
improv
viral
diagnosi
superior
sensit
specif
rapid
result
report
emmadi
et
al
natbas
infecti
diseas
test
provid
rapid
result
aid
outbreak
detect
ebola
genotyp
identif
hcv
identif
possibl
drug
resist
lead
rapid
clinic
therapeut
decis
earli
infect
control
prevent
spread
diseas
espi
et
al
viral
cultur
tradit
consid
gold
standard
viral
diagnosi
increas
sensit
compar
rapid
antigentest
method
howev
signific
limit
viral
cultur
long
time
result
reach
day
cmv
gleav
smith
shuster
pearson
improv
cultur
includ
introduct
shell
viral
cultur
reduc
result
turnaroundtim
tat
cmv
h
although
consid
vast
improv
certain
virus
requir
immedi
treatment
intervent
prevent
lifethreaten
infect
therefor
tat
simpli
much
long
relianc
viral
cultur
diagnost
test
introduc
pronounc
drawback
noteworthi
routin
virus
grow
cultur
viru
viabil
thu
cultur
abil
could
impact
sampl
collect
transport
condit
prior
patient
treatment
limit
mind
nat
test
tremend
advantag
replac
cultur
virus
due
greatli
reduc
tat
typic
less
h
still
retain
high
sensit
applic
nat
test
specif
realtim
quantit
pcr
technolog
viral
diagnost
confirmatori
test
continu
expand
cdcupdat
recommend
hiv
test
state
specimen
reactiv
initi
antigenantibodi
combin
immunoassay
nonreact
indetermin
antibodi
differenti
immunoassay
test
fdaapprov
nat
test
branson
branson
et
al
addit
nat
demonstr
util
highrisk
popul
antibodi
test
alon
might
miss
consider
percentag
hiv
infect
otherwis
detect
nat
virolog
test
priddi
et
al
stekler
et
al
particularli
immunoassay
hiv
diagnosi
limit
mark
delay
infect
seroconvers
time
hiv
viral
level
peak
figur
reason
nat
recommend
method
diagnosi
hiv
acut
phase
infect
day
postinfect
hiv
viral
rna
first
marker
manifest
approxim
day
postinfect
initi
acut
phase
infect
lindback
et
al
day
initi
detect
hiv
rna
antigen
level
rise
detect
level
use
fourthgener
immunoassay
mark
delay
need
rapid
diagnosi
identif
hiv
rna
especi
critic
earli
diagnosi
medic
warrant
acut
phase
hiv
infect
patient
typic
present
flulik
symptom
often
lead
misdiagnosi
misdiagnos
highest
risk
infect
prison
inmat
iv
drug
user
men
sex
men
msm
also
increas
risk
diseas
spread
chu
selwyn
therefor
use
realtim
pcr
test
method
abl
identifi
presenc
hiv
viru
initi
stage
critic
addit
nat
critic
earli
diagnosi
congenit
perinat
acquir
viral
infect
especi
infant
born
hivinfect
mother
tang
ou
matern
antibodi
hiv
persist
expos
infant
month
age
turn
prevent
use
antibodybas
assay
earli
diagnosi
infect
high
level
morbid
mortal
first
year
life
infect
infant
therefor
high
import
determin
infect
statu
quickli
expos
infant
implement
appropri
art
therapi
earli
van
rossum
fraaij
de
groot
addit
hiv
addit
virus
demonstr
exhibit
perinat
transmiss
includ
respiratori
viru
cmv
herp
simplex
viru
hsv
varicella
zoster
viru
vzv
hbv
enteroviru
rotaviru
human
papilloma
viru
prober
et
al
nat
test
may
serv
valuabl
tool
earli
intervent
especi
critic
neonat
popul
lack
fulli
develop
immun
system
addit
applic
hiv
diagnosi
nat
test
also
utilis
diagnost
hcv
although
diagnost
hcv
rna
realtim
pcr
test
predomin
use
confirm
posit
hcv
antibodi
result
cdc
hcv
nat
test
recommend
confirm
nonreact
hcv
antibodi
test
patient
suspect
recent
hcv
exposur
hcv
rna
detect
earli
week
postexposur
wherea
hcv
antibodi
detect
week
postinfect
ghani
strader
thoma
seeff
therefor
similar
strategi
outlin
hiv
nat
test
suitabl
detect
diagnosi
acut
phase
hcv
infect
immunocompromis
patient
weaken
immun
system
includ
hiv
posit
immunosuppress
drug
undergo
chemotherapi
may
lack
abil
gener
appropri
immun
respons
requir
antihcv
test
special
circumst
cdc
recommend
consid
hcv
rna
test
diagnos
viral
infect
rapid
diagnost
test
also
import
virus
high
potenti
creat
epidem
outbreak
throughout
histori
influenza
caus
mani
outbreak
notabl
spanish
flu
thought
respons
estim
million
death
taubenberg
moren
respons
possibl
futur
outbreak
world
health
organ
establish
pcrbase
influenza
test
firstchoic
diagnost
test
human
anim
influenza
convers
molecular
test
base
fact
assay
sensit
specif
detect
influenza
virus
compar
nonmolecular
method
nat
method
also
lower
likelihood
fals
posit
fals
neg
result
therefor
result
interpret
less
impact
communitybas
influenza
preval
cdc
influenza
introduct
rapid
molecular
test
provid
result
littl
min
extrem
benefici
especi
hospit
nurs
home
chronic
care
facil
earli
influenza
identif
prevent
outbreak
number
molecularbas
diagnost
test
expand
even
introduct
test
wnv
respiratori
syncyti
viru
hsv
rotaviru
even
recent
ebola
develop
improv
continu
made
realtim
pcr
technolog
reduc
cost
time
result
even
number
nat
diagnost
test
continu
increas
applic
realtim
pcr
diagnost
also
expand
patient
appropri
diagnos
link
care
partli
aid
quantit
realtim
pcr
clinician
often
consid
sever
baselin
factor
collect
help
guid
therapeut
decis
decis
base
seri
question
includ
treatment
option
avail
treatment
regimen
prescrib
long
patient
need
therapi
factor
influenc
therapeut
decis
includ
diseas
complic
patient
predisposit
prior
treatment
experi
viral
genotyp
viral
resist
profil
host
genet
profil
among
other
depend
viral
infect
quantit
baselin
viral
load
may
also
serv
import
role
help
guid
treatment
decis
tabl
past
year
pharmaceut
develop
clinic
trial
investig
cuttingedg
antivir
treatment
reli
heavili
data
gener
pcrbasedand
eventu
quantit
realtim
pcrbasedtechnolog
determin
safe
effect
drug
use
cobb
et
al
mackay
arden
nitsch
practic
guidelin
continu
refer
registr
nonregistr
studi
utilis
quantit
realtim
pcr
guid
clinician
laboratori
proper
implement
treatment
test
order
deliv
effect
personalis
care
patient
aasldidsaiasusa
kotton
et
al
extens
coutilis
realtim
pcr
wide
accept
goldstandard
technolog
measur
patient
quantit
viral
load
cours
treatment
decis
initi
treatment
chronic
hcv
infect
made
sever
baselin
factor
routin
consid
aasldidsaiasusa
among
complic
like
liver
fibrosi
stage
coinfect
hiv
hepatocellular
carcinoma
endstag
liver
diseas
genet
variat
like
hcv
genotyp
subtyp
resist
marker
prior
treatment
experi
outcom
associ
baselin
viral
load
measur
quantit
realtim
pcr
chronic
hcv
treatment
outcom
well
document
earlier
therapi
pegylatedinterferon
plu
ribavirin
given
lack
altern
therapeut
option
recommend
therapeut
decis
factor
jensen
et
al
pawlotski
histor
practic
guidelin
recommend
measur
baselin
viral
load
serv
initi
timepoint
requir
effect
monitor
treatment
without
prognost
indic
yee
curri
darl
wright
current
tremend
advanc
treatment
chronic
hcv
infect
employ
directact
antivir
daa
report
cure
rate
determin
svr
even
difficult
treat
hcv
patient
predomin
unit
state
high
potenc
drug
across
patient
popul
greater
import
numer
factor
includ
hcv
genotyp
prior
treatment
experi
determin
appropri
cours
treatment
recent
aasldidsa
practic
guidelin
still
recommend
baselin
quantit
viral
load
therapeut
decis
factor
howev
rapidli
evolv
field
hcv
treatment
recent
fda
approv
fixeddos
combin
drug
consist
two
daa
sofosbuvir
ledipasvir
treatment
hcv
manufactur
drug
label
includ
new
indic
quantit
realtim
pcr
indic
treatment
noncirrhot
patient
specif
baselin
viral
load
elig
shorten
therapi
indic
tremend
implic
accord
prescrib
inform
patient
baselin
viral
load
million
iuml
elig
shorter
therapi
durat
week
much
shorter
durat
patient
popul
harvoni
therapeut
decis
practic
first
kind
treatment
chronic
hcv
infect
like
recur
theme
daa
manufactur
strive
develop
high
efficaci
regimen
requir
shorter
treatment
durat
addit
shorter
treatment
durat
favour
patient
payer
consid
cost
achiev
svr
daa
may
improv
patient
drug
adher
complet
therapi
hep
c
onlin
much
quantit
realtim
pcr
help
develop
claim
particular
regimen
technolog
also
employ
numer
laboratori
aid
part
therapeut
decis
contrast
chronic
infect
treatment
patient
present
acut
phase
hcv
infect
within
first
month
exposur
recommend
aasldidsa
patient
hcv
infect
spontan
clear
aasld
idsaiasusa
therefor
care
monitor
hcv
rna
sensit
nucleic
acid
test
requir
order
confirm
spontan
clearanc
defin
hcv
rna
neg
two
specif
measur
quantit
qualit
realtim
pcr
assay
wide
use
purpos
given
compar
sensit
factor
influenc
art
decis
hivinfect
patient
includ
determin
pregnanc
aidsdefin
condit
acut
opportunist
infect
low
count
hivassoci
nephropathi
potenti
drug
interact
coinfect
hcv
hbv
hiv
resist
test
prior
treatment
experi
dhh
hiv
plasma
hiv
rna
viral
load
perform
wide
quantit
realtim
pcr
also
recommend
preart
decis
factor
specif
treatment
patient
depart
health
human
servic
dhh
hiv
recommend
patient
plasma
hiv
viral
load
cpml
prescrib
variou
regimen
option
otherwis
restrict
take
higher
viral
load
primarili
due
inferior
virolog
respons
patient
higher
viral
load
observ
clinic
studi
sax
et
al
clinic
trial
studi
employ
quantit
realtim
pcr
order
help
determin
cutoff
mani
lab
utilis
technolog
help
guid
hivtreat
clinician
decis
case
chronic
hbv
infect
sever
studi
shown
hepat
b
e
antigen
hbeag
high
level
hbv
dna
independ
risk
factor
subsequ
develop
cirrhosi
hepatocellular
carcinoma
chen
lin
et
al
chen
yang
et
al
iloej
et
al
howev
due
fluctuat
natur
chronic
hbv
infect
prognost
util
one
high
hbv
dna
level
singl
timepoint
limit
thu
hbv
baselin
dna
viral
load
along
hbeag
alanin
aminotransferas
alt
level
fibrosi
collect
aid
decis
treat
antivir
agent
well
hbv
antivir
regimen
choos
durat
treatment
lok
mcmahon
typic
patient
hbv
dna
viral
load
iuml
sign
liver
diseas
ie
high
alt
level
andor
signific
fibrosi
loss
hbeag
consid
immedi
treatment
antivir
wherea
patient
iuml
close
monitor
viral
load
chang
prior
treatment
patient
fall
rang
monitor
persist
viraemia
sign
liver
diseas
decid
treat
quantit
realtim
pcr
therefor
play
crucial
role
care
chronic
hbv
patient
treat
appropri
time
appropri
regimen
durat
greater
risk
liver
complic
unlik
treatment
guidelin
hcv
hiv
hbv
manag
cmv
solid
organ
transplant
associ
specif
quantit
cmv
viral
load
cutoff
order
make
therapeut
decis
kotton
et
al
partli
due
histor
lack
intern
standard
vari
assay
design
led
poor
interinstitut
correl
quantit
nat
addit
widespread
practic
univers
prophylaxi
cmv
antivir
medic
administ
patient
earli
posttranspl
period
continu
finit
period
time
diminish
clinic
util
baselin
viral
load
make
therapeut
decis
howev
recent
avail
cmv
intern
refer
standard
establish
viral
load
cutoff
appli
preemptiv
monitor
patient
prior
treatment
initi
may
soon
becom
wide
accept
institut
requir
determin
test
perform
characterist
clinic
cutoff
sever
studi
shown
low
cmv
virolog
threshold
eg
detect
viraemia
use
quantit
realtim
pcr
use
start
preemptiv
therapi
especi
highrisk
case
organ
donor
screen
posit
receptor
screen
neg
cmv
serolog
atabani
et
al
couzi
et
al
sun
cacciarelli
wagen
singh
among
varieti
baselin
risk
factor
may
indic
longer
cmv
treatment
durat
signific
predict
valu
demonstr
higher
baselin
viral
load
longer
treatment
durat
may
prevent
cmv
diseas
relaps
kotton
et
al
sia
et
al
clinic
trial
studi
support
recent
fda
approv
quantit
realtim
pcr
cmv
test
calibr
intern
standard
also
demonstr
clinic
valu
baselin
test
patient
cmv
diseas
undergo
treatment
anticmv
drug
ganciclovir
valganciclovir
razon
et
al
data
studi
suggest
patient
baselin
cmv
viral
load
iuml
like
resolv
cmv
diseas
rapidli
higher
baselin
viral
load
studi
need
determin
univers
threshold
preemptiv
therapi
initi
predict
valu
cmv
baselin
viral
load
defin
optim
treatment
durat
exist
clear
applic
quantit
realtim
pcr
technolog
baselin
determin
patient
signific
viral
infect
fact
quantit
viral
load
determin
play
critic
role
therapeut
decis
mani
viral
infect
high
baselin
viral
load
shown
correl
advanc
diseas
infect
numer
virus
bkv
ebv
adenoviru
may
potenti
need
longer
durat
therapi
certain
scenario
cincinnati
children
hospit
medic
center
domingu
lakeman
mayo
whitley
gustafson
et
al
randhawa
et
al
patient
baselin
assess
preemptiv
monitor
suggest
treatment
avail
treatment
regimen
choos
perhap
durat
therapi
patient
move
therapeut
administr
quantit
realtim
pcr
help
continu
set
stage
decis
potenti
save
live
reduc
complic
decreas
morbid
lessen
econom
burden
patient
healthcar
system
serial
measur
viral
load
serv
individualis
map
viral
infect
estim
amount
viru
found
within
infect
person
track
viral
load
continuum
care
vital
tool
use
predominantli
monitor
treatment
respons
effect
earli
sign
resist
emerg
therapi
chronic
viral
infect
viral
activ
reactiv
immunocompromis
patient
follow
bone
marrow
solid
organ
transplant
goal
treatment
chronic
hcv
infect
svr
patient
may
fail
therapi
due
nonrespons
ontreat
breakthrough
posttreat
relaps
figur
earli
chang
quantit
viral
load
time
may
predict
treatment
efficaci
shorten
therapi
patient
respond
rapidli
treatment
yee
et
al
responseguid
therapi
rgt
best
exemplifi
treatment
chronic
hcv
patient
specif
sooner
patient
becom
hcv
rna
undetect
treatment
lower
relaps
rate
treatment
shorten
convers
longer
take
patient
becom
hcv
rna
undetect
longer
need
remain
treatment
limit
relaps
howev
given
poorer
efficaci
earlier
regimen
patient
receiv
therapi
achiev
svr
reason
futil
rule
stop
rule
also
develop
requir
failur
patient
respond
target
detect
viral
load
cutoff
given
timepoint
indic
need
immedi
discontinu
therapi
monitor
hcv
viral
load
treatment
despit
advanc
treatment
hcv
patient
failur
achiev
svr
still
realiti
patient
achiev
svr
fall
four
categori
null
respond
black
line
achiev
less
decreas
hepat
c
viral
load
upon
treatment
partial
respond
red
line
light
grey
print
version
experi
least
decreas
hepat
c
viral
load
hcv
treatment
fail
proceed
undetect
viral
load
level
breakthrough
patient
orang
line
light
grey
print
version
undetect
hcv
viral
load
viru
rebound
treatment
relaps
blue
line
dark
grey
print
version
undetect
hcv
viral
load
viru
rebound
complet
hcv
treatment
although
rgt
notion
origin
develop
observ
made
treatment
older
therapi
pegifn
ribavirin
rgt
also
requir
treatment
much
potent
firstgener
daa
telaprevir
boceprevir
stop
rule
put
place
treatment
secondgener
daa
simeprevir
aasldidsaiasusa
ghani
et
al
yee
et
al
newer
ifnfre
daa
regimen
target
hcv
better
toler
patient
virtu
target
inhibit
higher
barrier
resist
yield
rapidli
declin
viral
kinet
thu
contain
treatment
indic
rgt
prescrib
inform
harvoni
olysio
sovaldi
viekira
rgt
major
driver
regular
viral
load
monitor
antivir
therapi
reason
monitor
hcv
viral
load
interv
baselin
measur
assess
svr
aasldidsa
guidelin
also
includ
recommend
monitor
initi
respons
week
treatment
repeat
week
detect
end
treatment
order
provid
assess
drug
complianceearli
efficaci
predict
treatment
outcom
respect
aasldidsaiasusa
recent
revis
webbas
guidelin
recommend
hcv
viral
load
increas
greater
repeat
test
week
thereaft
prompt
discontinu
hcv
treatment
mani
clinician
also
close
monitor
report
declin
viral
load
patient
order
demonstr
treatment
efficaci
motiv
patient
continu
treatment
remain
adher
drug
regimen
next
followup
appoint
fusfeld
et
al
regardless
monitor
hcv
treatment
rgt
adherencecompli
patient
motiv
earli
treatment
efficaci
etc
quantit
realtim
pcr
wide
use
laboratori
due
sensit
accuraci
reproduc
consecut
viral
load
test
patient
infect
chronic
viral
infect
hiv
lifelong
regimen
highli
activ
art
aim
suppress
hiv
viral
level
near
undetect
level
ensur
progressionfre
surviv
delay
togeth
prevent
progress
aid
reduc
potenti
transmiss
alongsid
monitor
immun
function
immunolog
efficaci
tcell
count
hiv
viral
level
critic
clinic
evalu
assess
hivinfect
patient
undergo
art
determin
patient
hiv
viral
load
indic
prior
entri
care
initi
art
week
art
initi
typic
everi
month
treatment
establish
baselin
level
hiv
viral
load
establish
viral
respons
therapi
assess
virolog
efficaci
art
monitor
abnorm
may
associ
antiretrovir
drug
dhh
hiv
baselin
hiv
viral
load
link
treatment
option
sax
et
al
also
help
establish
magnitud
viral
load
declin
initi
art
provid
prognost
inform
probabl
progress
aid
death
marschner
et
al
murray
elashoff
iaconoconnor
cvetkovich
strubl
thiebaut
et
al
treatment
initi
goal
reach
maintain
suppress
hiv
replic
determin
undetect
viral
level
utilis
highli
sensit
nat
test
gener
achiev
within
week
art
initi
need
sensit
assay
effect
assess
viral
suppress
hing
need
suppress
hiv
replic
extent
viral
evolut
drug
resist
mutat
emerg
typic
occur
patient
whose
hiv
rna
level
maintain
llod
current
realtim
quantit
pcr
assay
kieffer
et
al
due
introduct
sensit
realtim
pcr
assay
detect
viral
copiesml
natur
variabl
hiv
viral
level
time
even
patient
effect
suppress
much
evid
lima
harrigan
montan
gatanaga
et
al
willig
et
al
although
controversi
exist
clinic
signific
viral
load
llod
copi
ml
report
suggest
lowlevel
viraemia
predict
virolog
rebound
doyl
et
al
eron
et
al
lapris
de
pokomandi
baril
dufresn
trottier
virolog
failur
estevez
et
al
indic
drug
resist
taiwo
et
al
signifi
need
highli
sensit
assay
viraem
blip
singl
detect
hiv
viral
load
copiesml
otherwis
seemingli
suppress
patient
figur
howev
indic
subsequ
virolog
failur
develop
resist
mutat
castro
et
al
lee
kieffer
siliciano
nettl
nettl
et
al
blip
unusu
havlir
et
al
appear
common
winter
suggest
hostrel
season
factor
associ
occurr
viraemia
van
sighem
et
al
hand
persist
hiv
rna
level
copiesml
often
evid
viral
evolut
accumul
drug
resist
ontreat
hiv
patient
monitor
hiv
viral
load
fluctuat
patient
treatment
instanc
remain
undetect
dot
line
viral
blip
uncommon
result
transient
detect
even
quantifi
result
dash
line
b
virolog
failur
lead
sustain
highlevel
viral
titr
without
intervent
increas
time
mutat
aleman
soderbarg
viscocomandini
sitbon
sonnerborg
karlsson
et
al
treatment
failur
confirm
immedi
intervent
recommend
avoid
progress
accumul
resist
mutat
effect
respons
new
regimen
dhh
hiv
benefit
low
hiv
rna
level
andor
higher
cell
count
eron
et
al
even
brief
interrupt
therapi
may
lead
rapid
increas
hiv
rna
decreas
cell
count
increas
risk
clinic
progress
deek
et
al
lawrenc
et
al
develop
administr
newer
drug
target
specif
biolog
process
hiv
routin
clinic
monitor
viral
load
use
realtim
quantit
pcr
assay
continu
critic
predict
treatment
failur
earli
emerg
drug
resist
mutat
within
timefram
would
increas
subsequ
treatment
success
viral
load
monitor
also
essenti
recipi
solid
organ
transplant
cmv
seroposit
decis
made
initi
treatment
cmv
level
predict
diseas
reach
strategi
known
preemptiv
therapi
utilis
intens
monitor
cmv
activ
sensit
realtim
quantit
pcr
method
shortterm
antivir
treatment
given
signific
viral
count
symptom
occur
cmv
one
common
opportunist
pathogen
infect
solid
organ
transplant
recipi
fishman
associ
increas
morbid
mortal
saged
et
al
schnitzler
et
al
follow
primari
infect
viru
establish
lifelong
latent
infect
sever
site
bodi
may
reactiv
presenc
immunosuppress
transplant
recipi
reactiv
cmv
abl
modul
immun
system
known
potent
upregul
alloantigen
razon
increas
risk
chronic
allograft
dysfunct
reischig
saged
et
al
smith
et
al
acut
reject
saged
et
al
preemptiv
therapi
reduc
incid
cmv
diseas
khouri
et
al
reischig
et
al
document
seriou
problem
randomis
trial
upon
complet
univers
antivir
prophylaxi
therapi
kalil
levitski
lyden
stoner
freifeld
lowanc
et
al
paya
et
al
longterm
studi
demonstr
patient
receiv
preemptiv
therapi
compar
prophylaxi
therapi
less
like
develop
moderatetosever
kidney
scare
atrophi
significantli
better
surviv
transplant
organ
reischig
et
al
howev
challeng
still
exist
around
defin
appropri
threshold
initi
preemptiv
therapi
humar
snydman
new
standardis
realtim
pcr
assay
widespread
adopt
utilis
test
preemptiv
therapi
reli
intens
viral
load
monitor
may
becom
standard
certain
atrisk
patient
test
cure
end
treatment
respons
assess
follow
given
therapeut
regimen
sign
treatment
efficaci
case
quantit
viral
load
measur
serv
way
establish
cure
rate
other
may
use
confirm
virolog
suppress
clinic
cure
may
yet
possibl
current
therapi
technic
limit
realtim
pcr
limit
overal
sensit
viral
detect
regardless
clinic
util
measur
virolog
suppress
quantit
realtim
pcr
current
limit
detect
limit
quantit
valuabl
tool
measur
lowlevel
viraemia
establish
undetect
viral
load
utilis
quantit
realtim
pcr
assess
virolog
cure
perhap
best
exemplifi
treatment
patient
chronic
hcv
accord
aasld
idsa
guidelin
patient
undetect
hcv
rna
serum
assess
sensit
pcr
assay
week
complet
treatment
deem
achiev
sustain
virolog
respons
achiev
svr
consid
virolog
cure
hcv
infect
sinc
patient
hepat
crelat
liver
injuri
stop
recurr
infect
margin
detect
patient
year
posttreat
aasldidsaiasusa
mann
et
al
agreement
guidelin
fda
recommend
pharmaceut
daa
manufactur
also
stipul
viral
rna
clearanc
measur
clinic
trial
use
fdaapprov
sensit
specif
quantit
hcv
rna
assay
fda
hcv
accord
prescrib
inform
accompani
current
daa
threshold
defin
quantit
threshold
hcv
rna
iuml
week
end
treatment
feld
et
al
kowdley
et
al
lawitz
et
al
somewhat
dissimilar
aasldidsa
guidelin
undetect
viral
level
equival
detect
limit
quantit
figur
benefit
high
sensit
reproduc
quantit
realtim
pcr
clear
establish
role
assess
hcv
virolog
cure
clinic
trial
clinic
practic
abl
meet
need
assess
svr
quantit
realtim
pcr
may
also
play
critic
role
assess
cmv
diseas
resolut
consensu
guidelin
recommend
two
consecut
neg
sampl
obtain
minimum
treatment
cours
week
treatment
discontinu
thought
minimis
risk
develop
resist
diseas
recurr
asberg
et
al
chou
sia
et
al
still
transplant
centr
may
extend
treatment
secondari
prophylaxi
patient
compartmentalis
diseas
long
necessari
reduc
likelihood
recurr
cmv
infect
kotton
et
al
resolv
cmv
diseas
longterm
benefit
reduc
mortal
potenti
allograft
reject
risk
bacteri
fungal
viral
opportunist
infect
among
mani
transplantand
nontransplantspecif
effect
arthur
et
al
fishman
although
current
cure
hiv
infect
highli
sensit
quantit
qualit
realtim
pcr
test
target
total
hiv
dna
rna
use
clinic
studi
sterilis
elimin
hivinfect
cell
function
control
hiv
absenc
art
cure
kibirig
lewin
rouzioux
improv
realtim
pcr
technolog
may
lead
profound
increas
assay
sensit
abil
achiev
singlecopi
detect
cpml
may
lead
us
better
understand
hiv
virolog
may
need
therapeut
achiev
cure
alidjin
bocket
hober
therapeut
strategi
one
day
abl
achiev
hiv
cure
highli
sensit
test
doubt
play
key
role
continuum
care
patient
importantli
confirm
cure
clinic
laboratori
undergon
chang
becom
effici
flexibl
deliv
highqual
result
choos
implement
new
test
even
beyond
viral
target
laboratori
consid
first
foremost
perform
medic
valu
test
factor
tat
eas
use
cost
realtim
pcr
wide
dynam
rang
high
specif
high
sensit
consid
gold
standard
quantif
identif
varieti
target
includ
bacteria
fungi
virus
oncolog
mutat
klein
furthermor
multiplex
capabl
realtim
pcr
increas
number
target
inform
gather
test
improv
laboratori
workflow
tat
cost
deshpand
white
novel
technolog
enter
clinic
laboratori
includ
mass
spectrometri
nextgener
sequenc
realtim
pcr
remain
stapl
attract
option
clinic
laboratori
aim
creat
molecular
laboratorydevelop
test
ldt
addit
pcr
quickli
adapt
provid
robust
test
identif
emerg
diseas
molecular
test
abl
reach
beyond
clinic
laboratori
enhanc
healthcar
farrar
wittwer
foudeh
didar
vere
tabrizian
molecular
test
use
clinic
laboratori
fdaapprov
commerci
avail
instanc
howev
test
may
avail
specif
viru
sampl
type
andor
clinic
indic
use
laboratori
differ
fdaapprov
assay
typic
lead
laboratori
design
pcrbase
test
modifi
exist
assay
fda
defin
ldt
type
vitro
diagnost
test
design
manufactur
use
within
singl
laboratori
recognis
ldt
import
continu
develop
personalis
medicin
fda
ldt
laboratori
develop
test
group
three
categori
fdaclear
approv
test
modifi
test
subject
fda
clearanc
approv
test
perform
specif
provid
manufactur
eg
analytespecif
reagent
asr
burd
code
feder
regul
altern
sampl
type
applic
fdaapprov
test
often
modifi
fit
test
need
laboratori
includ
altern
collect
media
sampl
type
expand
clinic
applic
exampl
recent
gap
creat
hcvscreen
algorithm
confirm
posit
enzym
immunoassay
result
follow
discontinu
fdaapprov
confirmatori
test
alter
kuhnert
finelli
respons
cdc
publish
recommend
use
fdaapprov
test
detect
hcv
viraemia
cdc
hcv
despit
fact
assay
specif
claim
confirmatori
test
result
sever
laboratori
chose
valid
assay
ldt
meet
screen
need
hcv
addit
ldt
option
identif
aetiolog
agent
viral
infect
occur
transplant
patient
ebv
adenoviru
vzv
bk
viru
often
present
nonspecif
clinic
manifest
razon
fdaapprov
assay
option
lack
ldt
integr
part
molecular
laboratori
test
whether
creat
groundup
modifi
fdaapprov
assay
ldt
answer
clinician
need
inform
aid
diagnosi
treatment
patient
clinic
test
ldt
meet
minimum
standard
set
forth
clia
prior
report
patient
result
code
feder
regul
juli
fda
inform
congress
agenc
ldt
regulatori
oversight
framework
fda
ldt
fda
aim
address
concern
highrisk
ldt
inadequ
support
claim
lack
appropri
control
falsif
data
may
lead
inadequ
treatment
possibl
harm
patient
unnecessari
healthcar
cost
present
still
high
degre
uncertainti
final
regul
scope
possibl
impact
molecular
laboratori
seen
palaeopatholog
confirm
truism
human
sinc
incept
expos
genet
infecti
diseas
earli
document
trachoma
bce
tuberculosi
bce
pneumonia
ca
bce
aufderheid
rodreguezmartin
hershkovitz
et
al
robert
manchest
webb
even
today
emerg
infecti
diseas
eid
continu
appear
unpredict
driven
chang
human
demograph
land
use
popul
behaviour
lederberg
hamburg
smolinski
sehgal
taylor
latham
woolhous
infect
classifi
either
newli
emerginga
previous
unknown
diseas
reemerg
infecti
diseasesa
previous
known
diseas
reappear
signific
reduct
incid
elimin
moren
fauci
eid
threat
human
health
also
global
stabil
economi
effort
monitor
eid
place
global
level
spearhead
nation
level
unit
state
government
agenc
depart
health
human
servic
unit
state
agenc
intern
develop
depart
defens
support
activ
detect
assess
respond
potenti
outbreak
specif
pcr
realtim
pcr
easili
adapt
detect
nucleic
acid
target
uniqu
given
pathogen
play
essenti
role
identif
detect
infecti
pathogen
routin
use
health
organis
agenc
epidem
outbreak
sever
acut
respiratori
syndrom
sar
ebola
shuaib
et
al
influenza
sar
epidem
appear
novemb
chines
provinc
guangdong
reach
adjac
hong
kong
sar
sar
eventu
spread
countri
result
case
respons
cdc
trigger
emerg
oper
centr
issu
draft
genom
april
day
initi
global
alert
cdc
sar
soon
realtim
quantit
pcr
assay
describ
put
use
diagnosi
sar
drosten
et
al
peiri
et
al
host
measur
taken
order
contain
epidem
molecular
identif
diagnosi
infecti
agent
pcr
play
key
role
provid
critic
inform
address
situat
contribut
care
patient
infect
addit
reemerg
ebola
epidem
cdc
ebola
ebola
start
guinea
march
spread
nearbi
west
african
countri
eventu
reach
unit
state
europ
ebola
height
epidem
fda
issu
emerg
use
authoris
eua
use
first
realtim
rtpcr
assay
fda
eua
less
month
later
five
addit
realtim
pcr
test
authoris
eua
fda
eua
provid
earli
diagnosi
ebola
viral
diseas
cdc
ebola
eid
remain
constant
unpredict
threat
human
health
flexibl
realtim
pcr
technolog
continu
show
promptli
use
detect
infecti
agent
provid
rapid
diagnost
realtim
pcr
help
start
appropri
treatment
right
away
maximis
chanc
posit
outcom
goal
pointofcar
test
poct
quickli
obtain
test
result
use
implement
appropri
treatment
improv
clinic
outcom
definit
poct
laboratori
test
take
place
near
site
patient
cap
poc
advantag
poct
improv
tat
result
avail
regardless
normal
core
laboratori
hour
access
care
remot
area
greater
patient
involv
fight
aid
larg
contribut
develop
poct
devic
viral
load
capabl
hong
studer
hang
anderson
quak
lee
et
al
marcu
anderson
quak
tanriverdi
chen
chen
unitaid
vulto
et
al
origin
develop
meet
difficult
condit
associ
remot
place
far
core
laboratori
facil
often
found
develop
world
design
conveni
portabl
poct
devic
fast
turnaround
accur
result
extend
reach
healthcar
mind
poct
system
could
easili
use
develop
nation
hospit
within
clinic
physician
offic
pharmaci
correct
facil
mobil
health
unit
target
pathogen
benefit
immedi
action
result
accur
also
quick
result
critic
kiechl
holland
ultim
test
menu
avail
platform
drive
implement
complement
clinic
laboratori
core
test
ideal
molecular
poct
system
includ
medic
valu
simplic
fast
tat
rugged
remain
ongo
engin
challeng
howev
latest
advanc
microfluid
great
exampl
potenti
devic
bring
realtim
pcr
labonachip
closer
mainstream
diagnost
use
excit
time
molecular
poct
upcom
year
bring
new
system
perhap
paradigm
chang
world
healthcar
need
clinician
laboratori
patient
continu
evolv
applic
molecular
diagnost
pcr
past
decad
quantit
realtim
pcr
technolog
increasingli
phase
clinic
practic
potenti
presentday
applic
realtim
pcrbase
method
enumer
serv
advanc
experiment
approach
within
biolog
field
push
boundari
know
learn
well
diminish
empir
medic
identif
manag
viral
diseas
high
sensit
technolog
reduc
risk
commonli
transmit
transfus
ill
becom
integr
part
manag
varieti
viral
infect
provid
pretreat
prognost
inform
therapeut
effect
monitor
end
treatment
respons
assess
quantit
realtim
pcr
complement
serolog
test
detect
infect
within
preseroconvers
window
period
infect
immunovari
virus
abl
predict
therapeut
failur
sooner
tradit
method
allow
time
manag
respons
realtim
pcr
assay
rapidli
develop
case
emerg
epidem
crise
involv
new
pathogen
may
result
signific
health
threat
next
year
like
see
even
increas
expans
clinic
applic
nucleic
acid
quantif
particularli
follow
bone
marrow
solid
organ
transplant
newest
standardis
assay
may
provid
avenu
develop
consensu
manag
guidelin
initi
preemptiv
anticmv
treatment
drive
toward
hiv
erad
complet
elimin
viru
within
cell
infect
patient
innov
quantit
realtim
pcr
assay
design
continu
push
boundari
detect
introduc
assay
progress
lower
limit
detect
thu
quantit
realtim
pcr
facilit
advanc
qualiti
diagnost
achiev
research
medicin
patient
outcom
